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Abstract:  
Cytochrome P450s (CYPs or P450s) requires an interaction with their physiological 
redox partner, cytochrome P450 reductase (CPR) for efficient catalysis.  However in vivo 
CPR is in limited supply, existing in a 1:10 to 1:25 ratio to P450.  Additionally, studies in 
both microsomal and reconstituted systems have shown that the presence of one P450 
isoform can influence the catalytic activity of a different isoform.  In our study, it was 
examined whether the presence of CYP2E1 would influence CYP2B4’s catalytic 
properties.  The data demonstrate that CYP2E1 acts a potent inhibitor of CYP2B4-
mediated N-demethylation of benzphetamine (BNZ), with a Ki of 0.05 µM.  CYP2B4 
was found to be resistant to inhibition by CYP2E1 when an artificial oxidant, tert-butyl 
hydroperoxide, was used.  Alternatively, CYP2B4 was unable to inhibit CYP2E1-
mediated p-nitrophenol hydroxylation.  While determining the apparent KM of CYP2B4 
for CPR in the presence of increasing concentrations of CYP2E1, a dual competitive and 
non-competitive nature of CYP2E1 inhibition was exposed. At low concentrations of 
CYP2E1, CYP2B4’s KM for CPR increased by 13-fold with virtually no change in kcat.  
While at high concentrations of CYP2E1, CYP2B4’s KM decreased to levels comparable 
to those observed in the absence of CYP2E1, though the kcat also decreased by 10-fold.  
Moreover, CYP2E1 increased the KM of CYP2B4 for BNZ by 8-fold, however the KM 
was only partly decreased to that observed in the absence of 2E1 with the use of 
saturating concentrations of CPR.  CYP2B4 and CYP2E1’s individual KM for CPR are 
nearly equal. Yet, the KM values of CYP2E1 for CPR in the presence of CYP2B4 
deceases significantly. Therefore, these results suggest that the presence of CYP2B4 
enhances CYP2E1’s affinity for CPR, which may allow CYP2E1 to out-compete 
CYP2B4 for CPR.  
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Introduction:  
 
1. A Brief History: 
In 1958, the first report of cytochrome P450 (CYP or P450) was published by Klingenberg, who 
examined the absorption properties of P450s (1).  He noted that of the heme containing proteins 
of the rat microsomes designated as cytochromes b5, some had a characteristic absorbance at 450 
nm upon binding of carbon monoxide (CO) and reduction of the heme.  Further research by 
Omura and Sato established the name of this heme protein as cytochrome P450. They were able 
to separate what is now known as cytochrome P450 from cytochrome b5 (2).  Additionally, it 
was found that P420 is the denatured form of P450.  From the initial identification of P450, their 
findings gave birth to an area of major interest in the field of drug metabolism, toxicity, and 
steroid biosynthesis to name a few. 
 
Early investigators of cytochrome P450 examined the metabolic function of P450s. Specifically, 
they studied the metabolism of carcinogens, drugs, pesticides, vitamins, and steroids (3, 4, 5, 6, 
7).  Cytochrome P450 was found to catalyze monooxygenase reactions (8).  The mechanism of 
metabolism and the elucidation of the P450 catalytic cycle have continued to be areas of great 
interest study. The various substrates are metabolized by the microsomal P450 system, which is 
made up of three components: cytochrome P450, cytochrome P450 reductase, and phospholipid 
(9, 10).  By the late 1970s, researchers were able to purify microsomal P450s for further analysis 
of cytochrome P450, specifically functional analysis (11, 12).   
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As research continued, experimental evidence suggested that multiple isoforms of cytochrome 
P450 existed (13,14).  In the 1970s, with the development of new technology such as 
recombinant DNA and heterologous protein expressions, the hypothesis of multiple isoforms of 
P450s was confirmed (15).  The increasing number of P450s identified created a need for a 
naming system and in 1987 Nebert and co-workers developed one based on sequence identity 
(16).  The multiple isoforms of P450s have significantly different amino acid sequences.  These 
isoforms follow a nomenclature based on the sequence of the proteins.  The P450 name 
originates from the spectral absorbance at 450nm when a complex is formed between the 
reduced heme and CO.  P450s within the same family share 40% sequence identity on the amino 
acid level; this gives the assignment of a number (1, 2, 3, etc.) to identity the protein (26).  
Similarly, P450s that are members of the same subfamily share 55% sequence identity, giving 
the designation of a letter (A, B, C, D, etc.) (26).  The final number in P450 nomenclature marks 
(1, 2, 3, etc.) each individual cytochrome P450. 
 
Another major milestone in P450 research was the first crystal structure of P450cam from 
Pseudomonas putida, which provided greater insight to the structure of the P450 superfamily 
(17). Since then, other isoforms of P450 crystal structures have been reported, such as CYP2D6 
and 3A4 (18, 19).  In recent years, cytochrome P450 research has been focused on hepatic P450s 
due to their involvement in drug metabolism and thus they are of great pharmaceutical concern 
in understanding bioavailability, drug-drug interactions and toxicity.  Additionally, another area 
of on-going research is concerned with detailing the catalytic cycle along with P450 inhibitors, 
characterization of novel P450 isoforms, and continued efforts to crystalize different P450 
isoforms (20, 21, 22).  
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2. Background on Cytochrome P450: 
Cytochrome P450s are a large family of proteins that are found in most plants, animals, and in 
nearly every human cell type.  Mammalian P450s are membrane-bound hemoproteins.  P450 
structures are highly conserved; they are dynamic with a rigid core.  In general, P450 secondary 
structure consists of four to five beta sheets, eight to ten helices, and a central heme.  The unique 
folds of P450s are specifically adapted for the function of oxygen activation by heme-thiolate 
chemistry, the binding of redox partners (cytochrome P450 reductase (CPR) or cytochrome b5 
(Cyt b5)), and stereochemical selection of substrates (23).  The different isoforms of P450 are 
more structurally conserved closer to the heme center, specifically conserving the structures 
involved in heme-thiolate oxygen chemistry.  The high conservation can be seen in the helices I 
and L, which directly contact the heme.  Along with I and L helices, the β-bulge contains the Cys, 
which coordinates with the heme iron.  The Cys accepts a hydrogen bond from the peptide NH 
group, which helps to regulate the redox potential heme irons required for efficient P450 
reactions.  The greatest structural differences between the different isoforms can be seen in the 
areas controlling substrate specificity, such as the B’ helix.  The structure of CYP2B4, which is 
the topic of this study, can be seen with labeled helices and β sheets in Figure 1. 
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Figure 1: Cytochrome P450 2B4 with substrate bound.  The sequence follows from the blue 
N-terminus to the red C-terminus, with the heme shown in red sticks.  The major helices are 
labeled.  The image was taken from Scott et. al., who generated the image from a crystal 
structure using PyMOL (24). 
 
In the human liver, CYPs metabolize 60% of all exogenous compounds such as clinically used 
drugs.  Additionally, P450s metabolize many endogenous substrates such as steroids, fatty acids, 
and lipid soluble vitamins.  Furthermore, CYPs are known to transform some foreign chemicals 
into reactive toxins or mutagens. Cytochrome P450s are able to catalyze a wide variety of 
oxidative reactions, such as hydroxylation, epoxidation, N-, S-, and O-dealkyation, 
sulphoxidation, epoxidation, deamination, desulphuration, dehalogenation, nitrogen oxidation, 
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and peroxidation along with other oxidative reactions  (25).  The cytochrome P450 systems 
catalyze the following reaction scheme: 
RH + O2 + NAD(P)H + H+  → ROH + NAD(P)+ + H2O 
 
The P450 superfamily is able to metabolize a diverse range of substrates in almost all types of 
organisms.  The human liver is the primary site of drug metabolism by human P450s, thus these 
proteins are a topic of major medical research.  
 
The combination of multiple isoforms along with the highly dynamic conformational nature of 
P450s plays a role in the ability of human liver’s P450s to metabolize approximately 70% of all 
drugs, along with many steroids, fatty acids, and xenobiotics (27, 28).  The metabolic fate of a 
drug is determined not only by the interactions of that specific drug with the P450(s) that 
metabolizes the drug, but also on the potential of co-administered drugs to modulate the 
metabolic capability of the drug metabolizing P450.  For example, the co-administered drug may 
potentially induce the expression level of a P450 or the drug may directly inhibit the activity of 
the P450.  With the induced expression of a P450, the metabolism of a drug may be dramatically 
increased, thus lowering the concentration of the drug and preventing any therapeutic effects.  
Additionally, elevated levels of an individual P450 may alter the physiological levels of 
potentially essential compounds such as signaling molecules or hormones.  These changes in the 
concentration of P450 substrates can cause detrimental effects, such as drug-drug interactions. 
Furthermore, the inhibition of a P450 may prevent the metabolism of a compound and thus cause 
the accumulation of a drug or compound to harmful levels in the body.	   Due to these potentially 
adverse reactions, it is critical to have a thorough understanding of the P450 function and 
structure to predict and avoid potentially unfavorable drug-drug interactions.  Additionally, it is 
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important to have a comprehensive understanding of P450 mechanism and structure to avoid 
potentially adverse reactions. Thus, it is critical to understand how co-administered drugs may 
alter one another’s metabolism to prevent drug-drug interactions through the P450 metabolism 
system. 
 
3. The Catalytic Cycle 
For P450s to perform oxidative reactions, they depend on their interactions with their 
physiological redox partner, cytochrome P450 reductase (CPR).  The P450 catalytic cycle 
reveals the critical role that CPR plays in P450 mediated metabolism.  Research continues to 
elucidate new facets of the catalytic cycle.  The overall catalytic cycle can be seen in Figure 2 
(33).  In the resting state, the heme iron is in the ferric state (Fe3+) with an absorbance at 420 nm. 
The resting state of P450 is labeled as A in Figure 2.  The catalytic cycle is initiated with the 
binding of the substrate, which displaces a water molecule as the sixth ligand for the heme iron.  
The binding of the substrate induces the transition of the heme iron from a low spin state to a 
high spin state, with an increase absorbance at 390 nm and a decrease on the absorbance at 420 
nm which is referred to as a “Type I” difference spectrum (29).  Due to the slight change of the 
iron position relative to the plane of the porphyrin ring, this transition subsequently increases the 
P450’s redox potential from approximately -330 mV to -110 mV (29).  This transition is 
illustrated in the Figure 2 as the shift from A to B.  The change in redox potential results in the 
high spin P450 having a higher redox potential than the Flavin Mononucleatide (FMN) domain 
of CPR.  Thus an electron is transferred from CPR to the P450, causing the reduction of ferric 
P450 to ferrous (Fe2+) P450, which is now thermodynamically favorable.  The ferrous P450 in 
the is marked as C in the Figure.  In this new oxidation state, the heme iron allows for the capture 
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of molecular oxygen by the ferrous heme, forming a stable dioxygen adduct shown as D.  In 
Figure 2, D to E illustrates the delivery of a second electron from either CPR or cytochrome b5 
that then allows for the activation of bound oxygen, which is often the rate limiting step (29).  
Next, a quick protonation step occurs forming the ferric hydroperoxy complex (Fe3+-OOH), 
which is the first reactive species form and is known as “Compound 0” (30).  “Compound 0” is 
labeled as E’ in Figure 2.  This leads to a second protonation concurrently with the heterolytic 
cleavage of the O – O bond to produce a water molecule along with the highly reactive ferryl-
oxo species (Fe2+=O*), known as “Compound I”.  F in Figure 2 designates “Compound I”.  The 
reactivity of the cation radical allows for the insertion of an oxygen atom into the substrate (30).   
Finally, oxidation of the substrate by the oxyferryl intermediate results in product release and 
restores the ferric form of P450 (31,32).  
 
Figure 2:  The Catalytic Cycle of an oxidative reaction by P450 taken from Bumpus (33). 
The P450 catalytic cycle begins with A.  
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The majority of studies examining the catalytic properties of the P450 are performed in 
reconstituted systems and are typically conducted under saturating or near-saturating 
concentrations of CPR, where the CPR to P450 ratio is 1 or greater.  However, under 
physiological conditions in the endoplasmic reticulum (ER), P450s are known to exist in vast 
excess over CPR.  Many studies over the years have indicated that approximately 10 – 20 
molecules of P450 are present in the ER for every single molecule of CPR (34, 35, 36, 37).  
Although there is a wealth of information about the mechanisms that direct the reduction of 
P450s by CPR, there is not much known about the spatial organization and distribution of P450, 
cytochromes b5, and CPR within the membrane of the ER.  
 
Over the past forty years, several models have been proposed to describe the distribution of 
P450s and their redox partners in the lipid membrane of the ER (35, 36, 37, 38, 39).  One 
possible model that has been proposed is that the N-terminal hydrophobic tail of CPR firmly 
anchors the CPR in the membrane, while the CPR’s catalytic domain protrudes from the 
membrane into the cytosolic region of the cell.  In this model, it is envisioned that several P450s 
are clustered around a central CPR molecule and a portion of the microsomal P450s are loosely 
associated with the CPR and may be free-floating in the membrane (34, 38).  The difference in 
the ratio between P450 to CPR (34, 35, 36, 37), along with the probable organization of these 
microsomal proteins in the membrane suggests that only a portion of the total microsomal P450s 
can be in a functional complex, at a given time.  Thus, only a fraction of the total microsomal 
P450s are capable of drug metabolism at any given time.  Furthermore, the un-complexed P450s 
that remain would fundamentally be rendered metabolically silent until they are able to form 
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functional interactions with CPR.  Due to the limited number of CPR molecules relative to P450s, 
the outcome of P450-mediated drug metabolism may not just be a function of the particular P450 
that metabolizes the drug.  Thus, P450-mediated drug metabolism may also be a function of 
accessibility to CPR, which could be influenced by the presence and abundance of other P450s 
surrounding the CPR (40). 
 
4. P450-P450 Interactions 
In addition to potential drug-drug interactions in the cytochrome P450 system, there is also the 
possibility of protein-protein interactions that can lead to adverse reactions.  There is increasing 
evidence that P450s in the liver that are involved in metabolism form complexes in the 
endoplasmic reticulum (41). The formation of a protein complex begins with collision between 
the proteins.  As these collisions continue to occur, a complex begins to form through a transition 
state, moving through the energy landscape leading to lower energy state. The changes in energy 
follows a similar energy landscape as the fold of an individual protein (42).  The formation of a 
protein complex is largely influenced by electrostatic interactions (42).  Past studies by Schreiber 
showed the transitional state of the protein complex is stabilized by long-range electrostatic 
forces, which help to position the proteins before association (43).   
 
Recent research has shown that both homomeric and heteromeric P450-P450 complexes form in 
the ER of the human liver, which can significantly alter cytochrome P450’s function (41).  Reed 
and Backes proposed that there are potentially three models of interaction between P450s, 
leading changes in each P450’s activity (41).   
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The first model of interaction is just a simple competition between the two P450s for cytochrome 
P450 reductase, which is in limited supply.  In this first model, the relative affinity of the P450s 
for CPR and the ability of the P450-CPR complex to oxidize the substrate will determine which 
P450 has greater metabolic activity.  West and Lu examined interactions between CYP2B1 and 
CYP1A2 catalyzing the hydroxylation of 3,4-benzopyrene. They found that the interaction 
caused mutual inhibition by simple competition for CPR (44).  Tan. et. al. similarly found that 
interactions between CYP2A6 and CYP2E1 are simply due to competition by the P450s for the 
CPR (45).   
 
The second model of interaction is the potential formation of P450-P450 complex that affects 
cytochrome P450 binding to CPR.  The physical complex formed between the two P450s leads 
to a change in the affinity of the P450s for CPR; the interaction may increase or decrease the 
affinity.  Some experimental evidence of this was seen with the inhibition of CYP2B4 
metabolism of 7-pentoxyresorufin in the presence of CYP1A2, while CYP1A2 metabolism of 7-
ethoxyresorufin deethylation was shown to be stimulated by the presence of CYP2B4.  Analysis 
of this data illustrated that the formation of a CYP1A2-CYP2B4 complex results in an 
enhancement of the CYP1A2 affinity for CPR (34, 46, 47).   
 
A third model of interaction is the formation of a P450-P450 complex that affects the efficiency 
of substrate turnover.  One study found evidence suggesting that 3A4 – mediated 6β-
hydroxylation of testosterone was enhanced by up to four-fold in the presence of human, rat, and 
rabbit CYP1A2, though the degree of catalytic stimulation varied greatly depending on the 
species (48).  Additionally, interactions between P450s have also been reported for other major 
15 
drug metabolizing enzymes, such as CYP2D6 and CYP2C9 (49).  For this study, when CYP2D6 
was co-incubated with CYP2C9, the results showed a 50% decrease in the Vmax for the CYP2C9 
mediated hydroxylation of flurbiprofen, while there was almost no observed change in the KM.  
To determine the cause of inhibition at the pre-steady-state level, the Ks of CYP2C9 for 
flurbiprofen was measured in both the absence and presence of CYP2D6.  The data showed that 
CYP2D6 increased the Ks of 2C9 for flurbiprofen by 20-fold. Thus, these results suggest that 
CYP2D6-mediated perturbation of CYP2C9’s affinity for substrate is caused by conformational 
changes in the CYP2C9 active site architecture (49).   
 
Additionally, the physiological relevance and implication of such interactions have been 
investigated.  For example, the metabolism of methoxychlor by CYP2C19 has been shown to 
exhibit greater activity than CYP2C9 in a purified reconstituted system (50).  When the role of 
CYP2C19 versus CYP2C9 for methoxychlor metabolism was assessed in HLM, conflicting 
results were found. Using monoclonal antibodies raised against CYP2C19, no change was 
observed in methoxychlor metabolism. However, antibodies raised against CYP2C9 were 
effective in inhibiting methoxychlor-O-demethylation (51).  Finally, the metabolism of 
methoxychlor was examined in a binary reconstituted system that contained both CYP2C9 and 
CYP2C19. It was found that the demethylation of methoxychlor by CYP2C19 was significantly 
inhibited.   
 
These results suggest that interactions between P450 isoforms can alter their catalytic rates and 
complicate in vitro – in vivo drug metabolism predictions.  Some studies have shown that P450 
isoforms in the ER also interact. Alston et al. showed that a complex between CYP1A1 and 
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CYP3A1/2 alters the metabolism of benzo[a]pyrene in the membrane (52).  Such studies 
illustrate that P450-P450 interactions may play a role in in vivo drug metabolism. In addition to 
the interactions between the P450 isoforms indicated here there is evidence to support 
interactions occurring between many more P450s.  Some examples of isoform interactions 
include CYP2B4 and CYP1A2 (45, 46, 47), CYP1A2 and CYP2E1 (53), and CYP2C9 and 
CYP3A4 (54) 
 
5. CYP2E1 and CYP2B6 
The human liver contains many cytochrome P450s that play pharmaceutically important roles in 
the metabolism of drugs and toxins.  Both the CYP2E1 and CYP2B6 isoforms are known to play 
significant roles in liver toxicity and drug metabolism, respectively.  
 
Cytochrome P450 2E1 was first reported as an oxidant of ethanol over 40 years ago (55). It is 
estimated that CYP2E1 makes up 7% of the total P450 in the liver.  This 7% of P450 in the liver 
is responsible for the metabolism of 10% of clinically used drugs.  Several polymorphisms of 
CYP2E1 have been identified, although the significance of these polymorphism on in vitro and 
in vivo drug metabolism thus far has been shown to be negligible (22).  Recently, the crystal 
structure of CYP2E1 was solved.  This structure is the first experimental evidence of the 
isoform’s uncommonly small active site (56).  CYP2E1’s active site is estimated to have a 
volume of 190 Å3, rendering it the smallest known mammalian P450 active site thus far.  
CYP2E1 is known to bioactivate many low molecular weight compounds such as acetaminophen 
(57), N-ethyl nitrosamine (58) and carbon tetrachloride (59).  It is also known that CYP2E1 is a 
highly uncoupled P450. CYP2E1 is known to be highly inducible.  Induction of CYP2E1 protein 
17 
levels by alcohol (60) or fasting (61) likely contributes to an increase in the generation of 
reactive oxygen species (62).  The increase in reactive oxygen species can lead to oxidative 
stress.  CYP2E1s are of clinical interest due to their oxidation of particular drugs, oxidative 
stress, and activations of certain carcinogens.  
 
Approximately 1-5% of the total P450 in the liver is comprised of CYP2B6, and this metabolizes 
approximately 5% of clinically used drugs (22).  CYP2B6 plays an important role in the 
metabolism of a number of clinically important drugs, such as bupropion, cyclophosphamide, 
tamoxifen, efavirenz, and sertraline (63, 64).  Additionally, CYP2B6 is known to metabolize 
nicotine.  CYP2B6 has been found to be involved in the activation of some carcinogens.  
CYP2B6 has a highly polymorphic nature, which is of great importance in drug development 
because differences in amino acid composition are known to affect drug efficacy and toxicity.  
Nine single nucleotide polymorphisms have been identified, with 2B4K262R being the most 
common polymorphism. Unfortunately, the current heterologous expression system for 
recombinant human CYP2B6 in E. coli. has a very low yield.  Thus, the more highly expressing 
rabbit CYP2B4 is used as a model system to understand metabolism by CYP2B6 (65, 66).  
CYP2B4 is known to share approximately 80% sequence similarity with CYP2B6, and the 
CYP2B4 structure was recently shown to be effectively identical to CYP2B6 (67). 
 
Very little is known about how CYP2B4 and CYP2E1 interact with each other to modulate their 
catalytic activities, despite each having been studied extensively for their individual roles on 
metabolism and toxicity.  Hence, the purpose of this study was to assess, in a purified 
reconstituted system, whether CYP2E1 and CYP2B4 could influence each other’s metabolism 
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and then characterize the kinetic nature of such interactions.  Finally, this study will propose a 
preliminary model that explains the physical basis for the kinetic results.  
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Materials and Methods: 	  
Chemicals used during the project are all ACS grade and obtained from commercial 
vendors unless otherwise stated. The chemicals purchased from Sigma were benzphetamine, p-
nitrophenol, NADPH, sodium dithionite, ascorbic acid and tert-butyl hydroperoxide. 
Trifluoroacetic acid was purchased from Pierce Chemicals.  Dilauroylphosphatidylcholine 
(DLPC) was purchased from Doosan Serdary Research Laboratory (Toronto, Canada).  Carbon 
monoxide gas (purity >99.5%) was purchased from Cryogenic Gases (Detroit, MI).  
 
Construction of the CYP2E1 Y422D variant.  A QuickChange site-directed mutagenesis kit 
was used to preform site-directed mutagenesis according to the manufacturer’s protocol 
(Stratagene).  The forward and reverse mutagenic primers for Y422D are 
GGAAAGTTCAAGGACAGTGACTATTTCAAGCC and GGCTTGAAATAGTCACTGTCCT 
TGAACTTTCC, respectively.  The University of Michigan’s DNA Sequencing Core completed 
DNA sequencing to confirm the site-specific mutation. 
 
Overexpression and Purification of Enzymes.  Dr. James Halpert generously gave us the 
plasmids for the N-terminal truncated and C-terminal His-tagged CYP2B4dH (referred to as 
CYP2B4) and human CYP2E1.  Both the P450s and the CYP2E1 Y422D were over-expressed in 
Escherichia coli C41 (DE3) cells separately and purified using a Ni-NTA affinity column as 
described previously (68, 69).  The concentrations of CYP2B4 and CYP2E1 were determined 
using an extinction coefficient of ∆ε450-490 nm of 91 mM cm-1 as described by Omura and Sato (2).  
Additionally, NADPH-dependent cytochrome P450 reductase (CPR) was expressed and purified 
from Escherichia coli also as described previously (70).  The extinction coefficient of 21 mM 
cm-1 at 456nm was used to determine the concentration of CPR for the oxidized enzyme (71). 
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Determination of the Inhibition of CYP2B4 – Mediated N-demethylation of BNZ by 
CYP2E1 WT and the CYP2E1 Y422D variant.  The extent to which varying concentrations of 
either CYP2E1 WT or CYP2E1 Y422D inhibited the rate of formaldehyde formation by 
CYP2B4 (0.25 µM) was assessed at 37oC using a fixed concentration of CPR (0.5 µM) and BNZ 
(1.2 mM).  CYP2B4 was reconstituted in triplicate with increasing concentrations of 0.25, 0.5, 
0.75, 1.0, 1.25, 1.50 µM of CYP2E1 WT or CYP2E1 Y422D, CPR and 0.03 mg/ml DLPC on ice 
for 1 h.  The reconstituted mixtures were then combined with 50 mM potassium phosphate buffer 
(pH 7.4) and benzphetamine.  The samples where equilibrated at 37°C for 15 minutes.  The 
reactions were initiated in the samples by adding 7.5 µL of 20 mM NADPH for a final reaction 
volume of 500 µL.  The incubations proceeded for 5 minutes at 37°C before being quenched by 
the addition of 25 µL of 50% TFA.  Next, the protein was precipitated by centrifugation at 13.2k 
rpm for 5 minutes. Finally, a 500 µL aliquot of the supernatant was assayed for formaldehyde 
using the Nash reaction (72) 
 
Difference Spectra of the Carbon-Monoxy ferrous WT CYP2E1 and Y422D variant.  
CYP2E1 WT and the Y422D mutant (0.5 nml) were reconstituted with CPR (1 nmol) at 22°C for 
30 min in 0.5 ml of suspension buffer (100 mM potassium phosphate, 20% glycerol and 0.1 mM 
EDTA, pH 7.4). 100 µM 4-methylpyrazole and 0.5 mM NADPH were added to the sample for 
the baseline, then the samples were bubbled with CO.  The visible absorbance spectra were 
determined by scanning from 400 to 500 nm on a UV-2501PC spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan) until a steady state was attained with no further changes.  A trace 
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amount of sodium dithionite was added and additional scans were performed until no further 
change was detected. 
 
Determination of the Apparent Km and kcat Values for CYP2B4 for CPR Using the N-
demethylation of Benzphetamine in the Presence and Absence of CYP2E1.  At 37oC, the rate 
of formaldehyde formation as a result of the N-demethylation of benzphetamine was measured at 
a constant P450 concentration with increasing concentration of CPR to determine the Km and kcat 
values of the CYP2B4 WT for CPR, as previously described (73).  CYP2B4 WT (0.25 µM) was 
reconstituted in triplicate with varying concentrations of CPR (0.1, 0.2, 0.3, 0.6, 0.8, 1.2 and 1.4 
µM) and 0.03 mg/ml DLPC on ice for 1 h.  The reconstituted mixtures were added to 50 mM 
potassium phosphate buffer (pH 7.4) and 1.2 mM BNZ.  The samples were allowed to equilibrate 
at 37o C for 15 minutes. Then the reactions were initiated by adding 7.5 µL of 20 mM NADPH 
for a final reaction volume of 500 µL.  The reactions were incubated for 5 minutes at 37 o C 
before being quenched by the addition of 25 µL of 50% TFA.  The samples were centrifuged at 
13.2k rpm for 5 minutes to precipitate the proteins.  Then a 500 µL aliquot of the supernatant 
was assayed for formaldehyde using the Nash reaction.  GraphPad Prism 5.0 from GraphPad 
Software (La Jolla, CA) was used to fit the data to the Michaelis – Menten equation to determine 
the kinetic parameters.  To assess the effect of CYP2E1 on the Km and kcat of the CYP2B4 – 
CPR complex, the procedure outlined above was repeated in the presence of 0.125, 0.25, 0.75, 
1.25, and 1.50 µM CYP2E1. 
 
Graphical Analysis of Steady-State Activity Data.  Using GraphPad Prism, a Lineweaver-
Burk plot was obtained using the inverse of the reaction velocities obtained for the determination 
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of the Km and kcat values for CYP2B4 and CPR. These were plotted against the inverse of the 
concentrations of CPR used under varying concentrations of CYP2E1.  The Ki was obtained for 
CYP2E1 as a competitive inhibitor of CYP2B4 – CPR complex by using two methods.  First, a 
non-linear global fitting analysis of the data was done using GraphPad Prism. The second 
method involved plotting Km obs against varying concentrations of CYP2E1. The Ki was obtained 
from the x-intercept of a linear regression analysis of this plotted data (74). 
 
Characterization of the tert-Butyl Hydroperoxide-supported Metabolism of 
Benzphetamine by CYP2B4 WT in the Presence of Increasing Concentrations of CYP2E1 
WT.  To establish the rates for the tert-butyl hydroperoxide-supported metabolism of 
benzphetamine, a final concentration of 0.25 µM CYP2B4 WT was incubated at 37oC for 15 
minutes with 0.03 mg/ml DLPC, 50 mM potassium phosphate buffer (pH 7.4), and 1.2 mM 
benzphetamine.  Then, 52.5 µL of 1 M tert-butyl hydroperoxide was added, resulting in a final 
volume of 500 µL. The reactions were allowed to proceed for 5 minutes, after which they were 
terminated by the addition of 20 µL of 50% TFA.  Following termination, the samples were 
centrifuged at 13.2k rpm for 5 minutes and 500 µL aliquots of the supernatants were assayed for 
formaldehyde using the Nash Reaction.  This procedure was then repeated in the presence of 
0.25, 0.5, 0.75, 1.0, 1.25, 1.50 µM of CYP2E1 WT.  
 
Determination of the Km and kcat Values for the Metabolism of Benzphetamine by CYP2B4 
in the Absence and Presence of CYP2E1 WT.  The Km and kcat values for BNZ metabolism by 
CYP2B4, in the absence and presence of CYP2E1, were determined at 37oC at constant P450 
and CPR concentration with increasing concentrations of BNZ.  The CYP2B4 WT protein (0.50 
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µM) was reconstituted in triplicate with equal concentration of CPR and 0.03 mg/ml DLPC with 
and without 2 µM of CYP2E1 WT on ice for 1 hour.  Next, the reconstituted mixtures were 
added to 50mM potassium phosphate buffer (pH 7.4) with varying concentrations of 
benzphetamine, 0.05, 0.1, 0.2, 0.4, 0.6, and 0.8 µM.  The samples were equilibrated at 37oC for 
15 minutes. Then the reactions were initiated by adding 7.5 µL of 20 mM NADPH for a final 
reaction volume of 500 µL.  The incubations proceeded for 5 minutes at 37oC and then were 
quenched by the addition of 25 µL of 50% TFA.  The protein was then precipitated by 
centrifugation at 13.2k rpm for 5 minutes and 500 µL aliquots of the supernatant was assayed for 
formaldehyde formation using the Nash reaction.  Next, it was tested whether the Km could be 
decreased to the initial value in the absence of 2E1 by using saturating concentrations of CPR. 
This experiment was repeated in the presence of 2.5 µM CPR.  Using GraphPad Prism 5.0, the 
data were fit to the Michaelis – Menten equation to determine the kinetic parameters.  
 
Spectral Dissociation Constant (Ks) for the binding of BNZ to CYP2B4 in the Absence and 
Presence of CYP2E1.  The previously mentioned measurement of type I spectral changes was 
used to spectrophotometrically monitor BNZ binding to ferric CYP2B4 (75).  Equal volumes of 
P450 solutions containing 1 µM CYP2B4 in the presence or absence of 4 µM CYP2E1, 0.1 M 
potassium phosphate (pH 7.4) and 0.1 mg/ml DLPC were added to both the sample and the 
reference cuvettes.  The baseline was recorded after thermal equilibration at 30oC for 5 minutes.  
CYP2B4 in the sample cuvette was titrated with aliquots of 20 mM BNZ, while equal volume of 
water was added to the reference cuvette.  The difference spectra were recorded from 350-500 
nm. The difference in absorbance between the wavelength maximum (386 nm) and the minimum 
(421 nm) were plotted as a function of varying BNZ concentration (5-1200 µM). The data was 
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then used to obtain the Ks by fitting to Equation 1. 
                                                                                   Eq. 1
 
 
Determination of the Apparent Km and kcat Values of CYP2E1 for CPR Using 
Hydroxylation of p-nitrophenol in the Absence and Presence of CYP2B4.  At saturating 
concentrations of pNP, a fixed concentration of CYP2E1 and varying concentrations of CPR 
were used to determine the KM and kcat of CYP2E1 for CPR.  Samples of 0.1 µM of CYP2E1 
were reconstituted with varying concentrations of CPR (0.08, 0.12, 0.24, 0.72, 1.44, 2.00 µM) 
and 0.03 mg/ml DLPC in the presence and absence of 0.1 µM of CYP2B4 on ice for 1 hr.  Next, 
the reconstituted mixtures were added to 50 mM of potassium phosphate buffer (pH 7.4), 0.3 
mM pNP, and 2.0 mM ascorbic acid.  The samples were allowed to equilibrate at 37oC for 15 
minutes.  Once equilibrated, the reactions were initiated by adding 20 µL of 20 mM NADPH for 
a final reaction volume of 1000 µL.  The reactions proceeded for 20 minutes at 37oC and then 
they were quenched by 300 µL 20% TCA.  After quenching the reactions, the samples were 
incubated on ice for 10 minutes and then centrifuged at 13.2k rpm for 5 minutes. The samples 
absorbance of the samples was then measured at 510 nm by transferring a 1000 µL aliquot to a 
cuvette containing 100 µL of 10M NaOH.	  
 
€ 
ΔA =
ΔΑ
max
× BNZ[ ]
K
s
+ BNZ[ ]
25 
Results:  
 
Effect of Increasing Concentrations of CYP2E1 on BNZ metabolism by CYP2B4.  It 
has been previously established that CYP2B4 N-demethylates BNZ to form primarily 
norbenzphetamine and formaldehyde under the experimental conditions used in this assay.  
The product, formaldehyde is then reacted with the Nash reagent to form a conjugate 
species that absorbs maximally at 412 nm.  Hence, for these studies it is necessary 
preclude the possibility that CYP2E1 metabolizes BNZ to form formaldehyde or any 
other product detectable by this assay. Previously established methods were used to 
determine CYP2E1 metabolism of BNZ.  The results demonstrate the BNZ is primarily 
metabolized to nor-benzphetamine by CYP2B4 (data not shown).  Additionally, the data 
showed that metabolism of BNZ by CYP2E1 is insignificant compared to CYP2B4, even 
at high concentrations of CYP2E1 (data not shown).  The converse was also shown to be 
true for p-NP metabolism by CYP2E1. Thus these control experiments established that 
the N-demethylation of BNZ activity to form formaldehyde is specific for CYP2B4 
activity, while the hydroxylation of p-NP to form 4-NC is specific for CYP2E1 activity.  
 
Increasing concentrations of CYP2E1 were reconstituted with CYP2B4, CPR, and DLPC 
to determine the extent to which CYP2E1 could inhibit the catalytic activity of CYP2B4 
toward its probe substrate BNZ.  Increasing concentrations of CYP2E1 inhibit the 
activity of CYP2B4, up to approximately 80% loss of activity was observed in the 
presence of CYP2E1 compared to in the absence of CYP2E1, which can be seen in 
Figure 3.  Additionally, the data show that inhibition can be fit to a rectangular 
hyperbolic function and follows saturation kinetics.  The BNZ catalytic activity supported 
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by tBHP was characterized and compared to that supported by CPR.  These studies were 
used to determine whether the decrease in activity is due to disruption of the interaction 
of CYP2B4 with CPR or due to direct interaction between CYP2B4 and CYP2E1 that 
decreases the catalytic activity of the 2B4.  Hydroperoxides and other artificial oxygen 
donors are able to support the catalytic turnover of P450s in the absence of redox partners 
such as CPR.  When the effect of increasing concentrations of 2E1 on BNZ mechanism 
by 2B4 was determined in the presence of tBHP, CYP2B4 was barely inhibited by 
CYP2E1.  Thus the decrease in the CPR – supported BNZ activity suggests inhibition is 
not likely due directly to CYP2B4 – CYP2E1 interactions, but instead due to an effect on 
CPR – 2B4 interactions.   
 
Additionally, the ability of CYP2B4 to modulate the metabolism of p-NP by CYP2E1 
was examined.  The results of these investigations are shown in Figure 3B. They 
demonstrate that CYP2B4 does not inhibit the catalytic activity of CYP2E1 and that the 
inhibition detected in the mixed reconstituted system is solely a property of CYP2E1 
toward CYP2B4.  
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Figure 3A. CYP2B4 mediated N-demethylation of BNZ in the presence of increasing 
concentrations of CYP2E1.  The rate of BNZ N-demethylation by CYP2B4 was 
assessed as described in Material and Methods.  Formaldehyde formation was measured 
using either CPR/NADPH (◼) or t-BHP (), to support the activity to try to distinguish 
between the effects of direct CYP2E1 – CYP2B4 interactions on CYP2B4 activity versus 
competition for CPR.  Saturating BNZ (1.2mM) was used to compensate for any possible 
perturbation in substrate binding affinity perpetrated by direct P450-P450 interactions.  
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Figure 3B.  CYP2E1 mediated p-NP hydroxylation in the presence of increasing 
concentrations of CYP2B4.  The CYP2E1 – mediated hydroxylation of p-NP was 
assessed in the presence of increasing concentrations of CYP2B4 and saturating p-NP.  
The data points for BNZ and p-NP metabolism represent the mean of three triplicate 
experiments. The error bars represent the standard deviations.  
 
Inhibition of CYP2B4 activity by the Y422D variant of CYP2E1.  The conclusions 
described by Lin et. al. (76) led us to express and purify CYP2E1 Y422D to analyze 
whether the inhibitory event seen in Figure 3A was caused by the CYP2E1 – CPR 
interactions.  The Y422 residue of CYP2E1 has previously been shown to be nitrated by 
peroxynitrite.  This modification contributed to a loss in CPR – supported CYP2E1 
activity when compared to the tBHP-supported activity.  It is postulated that the highly 
negatively charged FMN domain of CPR interacts with the proximal side of CYP2E1 and 
therefore, we hypothesized that replacing Tyr with Asp by site-directed mutagenesis 
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would create a charge repulsive interaction between CYP2E1 Y422D and its residue 
counterpart in CPR.  This charge repulsion would then perturb the apparent affinity of the 
two proteins for one another.  Our lab’s previous stopped-flow studies have shown that 
the extent of formation of the reduced CO – complex supported by NADPH is an 
indicator of the degree of P450 – CPR complex formation. This reflects the affinity of the 
P450 under investigation for CPR (73).  The extent of Y422D reduction by CPR and 
NADPH compared to reduction of WT enzyme by CPR and NADPH can be established 
by measuring the absorbance of Y422D–CO complex at 450 nm and comparing this to 
the absorbance of WT-CO complex at 450 nm.  The results shown in Figure 4A 
demonstrate that the interaction of CYP2E1 Y422D with CPR decreases by more than 
50% compared to the WT.  The inhibitory potential of the Y244D mutant was examined 
with CYP2B4.  The results show that it inhibited the activity of CYP2B1 to a 
significantly lesser extent than CYP2E1 WT as can be seen in Figure 4B. 
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Figure 4A. Reduced CO spectra of WT CYP2E1 (left graph) and the CYP2E1 
Y422D variant (right graph).  In order to determine whether the mutation of Try 422 to 
Asp perturbed the binding of CPR to this variant, the CO absorbance difference spectrum 
was measured in the presence of CPR and NADPH following reconstitution, ensuring 
complete complex formation.  Samples (i) and (iii) were chemically reduced with 
dithionite while samples (ii) and (iv) were reconstituted with CPR and reduced by 
addition of NADPH. 
 
(i)	  
(ii)	  
(iii)	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Figure 4B.  The inhibition of CYP2B4 BNZ activity by CYP2E1 Y422D.  To establish 
the role of CYP2E1 in the inhibition seen in Figure 3A, Y422D was evaluated with 
regard to its ability to inhibit CYP2B4 activity (open bars) and then compared to WT 
CYP2E1 (filled bars). 
 
Determining the KM and kcat Values for the Interaction of CYP2B4 WT with CPR.  
The formation of a complex between CPR and CYP is an essential step in the transfer of 
electrons to the heme of the CYP that is required for substrate oxidation in the catalytic 
cycle.  The rate of substrate oxidation has been proposed to be directly proportional to the 
concentration of CPR – CYP2B4 complex (77, 78).  Therefore, measuring the rate of 
BNZ oxidation by a fixed concentration of CYP2B4 with the addition of increasing 
concentrations of CPR can be used to determine the KM and kcat of 2B4 for CPR across a 
range of CYP2E1 concentrations.  Comparison of these kinetic parameters determined in 
the presence of increasing concentrations of CYP2E1 can be used to examine the kinetic 
nature of the inhibitory interaction, as illustrated in Figure 3A.  Competition between 
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CYP2E1 and CYP2B4 should disrupt formation of the CYP2B4 – CPR catalytic 
formation and thereby increase the concentration of un-complexed CYP2B4.  The un-
complexed CYP2B4 would be unable to oxidize substrate, thus leaving it metabolically 
silent.  Figure 5 shows that the rate of BNZ oxidation as a function of varying CPR 
concentrations follows a rectangular hyperbolic relationship, which can then be fit to the 
Michaelis – Menten equation, and that the addition of increasing concentrations of 2E1 
does not alter that relationship but, does inhibit BNZ in a concentration-dependent 
manner.  CYP2E1 concentrations between 0.125 - 0.75 µM increased the KM of CYP2B4 
for CPR by 14 fold, while the kcat remains practically the unchanged. This is 
demonstrated in Figure 5 and Table 1.   
 
Figure 5. Determination the apparent KM and kcat values of CYP2B4 for CPR in the 
presence of increasing concentrations of CYP2E1 WT.  The formation of  
formaldehyde was measured at a constant concentration of CYP2B4 (0.2 µM) with 
increasing concentrations of CPR as indicated in the presence of varying concentrations 
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of CYP2E1 WT. These measurements were done as described in Materials and Methods.  
The error bars on the graph are the standard deviations from the three measurements. 
 
Table 1 
[2E1] µM KM CYP2B4-CPR (µM) kcat CYP2B4-CPR (min
-1) 
0.00  0.16 ± 0.030  130.0 ± 3.9 
0.125  0.29 ± 0.028  91.1 ± 2.8 
0.25  0.99 ± 0.18  110. ± 11. 
0.75  2.1 ± 0.73  110. ± 26. 
1.25  0.31 ± 0.078  36. ± 3.0 
1.50  0.36 ± 0.11  12. ± 1.3 
 
Table 1. Determination of Km and kcat values for the interactions of CYP2B4 and 
CPR in the presences of increasing concentrations of CYP2E1 WT.  The KM and kcat 
values were determined from the data in Figure 5 as described in Materials and Methods.   
 
Concentrations of CYP2E1 above 0.75 µM exhibited an unusual kinetic behavior 
observed with the kcat decreasing by 10-fold, while the KM value decreased to 0.36 µM in 
the presence of 1.50 µM CYP2E1.   
 
Linear Regression Analysis of the Steady-State Activity Data.  Plotting the inverse of 
the BNZ activity against the inverse of CPR concentrations as a function of varying 
CYP2E1 concentrations showed that the steady – state activity data could be divided into 
two sets based on whether the linear regression analysis intersected at a common value on 
the y-axis but diverged on the x-axis or whether they diverged on the y-axis and 
intersected on the x-axis.  Figure 6A shows that for the lower concentrations of 2E1 (0.0 
to 0.75 µM), CYP2E1 behaves as a competitive inhibitor since the KM increases 
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significantly, while the kcat remains relatively unchanged.  Figure 6B demonstrates the 
non-competitive inhibition by CYP2E1 with a KM value for 1.25 and 1.50 µM CYP2E1 
that is relatively similar to the KM observed in the absence of CYP2E1, while the kcat 
decreases significantly.  Thus, CYP2E1 appears to inhibit formation of the CYP2B4 – 
CPR complex by acting as a competitive inhibitor at low concentrations and at high 
concentrations it acts as a noncompetitive inhibitor of the CYP2B4 – CPR complex 
formation.  
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Figure 6A. 
 
Figure 6B 
 
Figure 6. Lineweaver – Burk Plot of the Steady-State Activity Data Shown in Figure 
5. From plotting the inverse rate of formaldehyde formation against the inverse of CPR 
concentration as a function of varying CYP2E1 concentrations, we observed that this data 
could be divided into sets based on whether the linear regression intersection occurs at a 
common intercept.  With concentrations of CYP2E1 WT between 0 – 0.75 µM, the CYP 
2E1 displayed competitive inhibition kinetics, seen in Figure 6A.  While at higher 
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concentrations of CYP2E1, CYP2E1 behaved as a noncompetitive, as seen in Figure 6B.  
 
In order to estimate the Ki for CYP2E1 as a competitive inhibitor of CYP2B4 – CPR 
complex formation the KM obs was plotted as a function of the CYP2E1 concentration.  
The data were fit to a straight line that intersected with the x-axis at an absolute value of 
0.05 µM as is shown in Figure 7. Consequently, CYP2E1 is an effective inhibitor of CPR 
binding to CYP2B4 with a nanomolar affinity. 
 
Figure 7.  Plot of KM obs versus CYP2E1 concentration.  The KM app values were 
obtained from study of the activity data in Figure 5.  The linear regression analysis for 
CYP2E1 concentrations ranging from 0 to 0.75 µM is shown as the solid line on the 
graph.  The Ki is determined from the absolute value of the x-intercept of the line.  
 
Steady-state activity of CYP2B4 for BNZ metabolism in the presence and absence of 
CYP2E1.  It has been previously suggested that there is an interplay between redox 
partner affinity and substrate affinity for P450s (79).  The binding affinity of BNZ to 
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CYP2B4 may be enhanced by the interaction between CYP2B4 and CPR and vice-versa.  
Thus, we hypothesized that an alteration in CYP2B4 – CPR complex formation by 
CYP2E1 should be reflected in modifications in the kinetic parameters of CYP2B4 for 
BNZ, its substrate.  Titrating increasing concentrations of BNZ with fixed concentrations 
of CYP2B4 and equal concentrations of CPR were used to determine the KM and kcat of 
CYP2B4 for its substrate.  The experiment was repeated with a four-fold concentration of 
CYP2E1 over CYP2B4.  The results of the experiment showed that the KM increases by 
8-fold, yet the kcat remains almost unchanged. These results are illustrated in Figure 8 and 
Table 2. If the increase in KM for BNZ is due to competition between CYP2E1 and 
CYP2B4 to be reduced by CPR, then supplying saturating concentrations of CPR should 
alter the binding equilibrium in favor of the CYP2B4 – CPR complex.  This is 
demonstrated by the recovery of CYP2B4 activity at high concentrations of CPR, which 
is seen in Figure 8.  Thus, the KM and kcat of CYP2B4 for BNZ in the absence and 
presence of CYP2E1 was determined under saturating concentrations of CPR, where 
CPR was 5-fold over the concentration CYP2B4.  The results indicated that the presence 
of saturating concentrations of CPR enhanced the KM of CYP2B4 for BNZ. In the 
absence of CYP2E1, there was a 28% enhancement. While in the presence of CYP2E1, 
there was a 75% enhancement relative to the sub-saturating concentration of CPR.  These 
results are consistent with the data shown in Figure 8.  Together these results suggest that 
the presence of saturating CPR reduces the inhibitory effects of CYP2E1 on CYP2B4.  
The removal of this inhibition caused by CYP2E1 leads to an incomplete yet significant 
recovery of the KM of CYP2B4 for BNZ.  
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Table 2 
 CYP2B4 
 Control Plus CYP2E1 Plus saturating CPR 
Plus CYP2E1 and 
saturating CPR 
KM (mM)  0.075 ± 0.010  0.60 ± 0.13  0.17 ± 0.051  0.060 ± 0.012 
kcat (min-1)  32 ± 0.78  33 ± 3.7  30 ± 3.0  35 ± 1.6 
 
Table 2.  The effect of CYP2E1 WT and CPR on KM and kcat values for the 
metabolism of BNZ by CYP2B4.  Measuring formaldehyde formation using Nash 
reagent was used to determine the rate of BNZ N-demethylation by CYP2B4 as described 
in Materials and Methods.  These measurements are demonstrated in Figure 8. 
 
Figure 8.  Effect of CYP2E1 and CPR on the kinetics of BNZ metabolism by 
CYP2B4.  To investigate the effect that CYP2E1 has on CYP2B4 substrate affinity, the 
KM and the kcat values for BNZ metabolism by CYP2B4 were determined.  The 
experiments had 0.50 µM CYP2B4, which was then titrated with increasing 
concentrations of BNZ as described in Materials and Methods. The method was 
conducted under the following conditions, (£) 0.50 µM CPR, (r) 0.50 µM CPR + 2 µM 
CYP2E1, (p) 2.50 µM CPR + 2 µM CYP2E1, and (¢) 2.50 µM CPR. 
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The effect of CYP2E1 on the Spectral Binding Constant (Ks) of BNZ CYP2B4.  The 
incubation of CYP2B4 with excess CPR was preformed in attempt to decrease the KM of 
BNZ for CYP2B4 to that observed in the absence of 2E1, but this was only partially 
successful, as shown in Table 2 and Figure 8.  From this information, we hypothesized 
that an additional mechanism of substrate inhibition may be responsible for the observed 
difference.  Previous CYP2B4 inhibition studies by CYP2E1 were performed in the 
presence of excess BNZ (1.2 mM).  Thus a disturbance in CYP2B4’s affinity for BNZ by 
the presence of CYPR2E1 may have been overlooked in these past studies.  It is known 
that BNZ induces a type I spectral shift of CYP2B4, but BNZ does not cause this shift in 
CYP2E1 (data not shown).  The type I spectral shift of CYP2B4 can be used to determine 
the effect of CYP2E1 on CYP2B4’s affinity for its substrate, BNZ.  The data in Figure 
9A, C show that BNZ binds to CYP2B4 with a Ks of 11.4 µM, and that in the presence of 
CYP2E1, (Figure 9B, C) the Ks increases by 30 fold to 339 µM.  These results show that 
CYP2E1 not only inhibits the affinity of CYP2B4 for CPR, but that CYP2E1 also inhibits 
CYP2B4’s affinity for BNZ.  
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Figure 9A           Figure 9B 
 
          Figure 9C 
 
Figure 9.  Type I spectral binding titrations for the binding of BNZ to CYP2B4.  The 
spectral changes at 386 nm and at 421 nm were induced by the addition of increasing 
concentrations of BNZ to 1 µM CYP2B4, as shown in Figure 9A in the absence of 
CYP2E1.  Figure 9B shows the spectral changes observed in the presence of 4 µM 
CYP2E1.  The titrations were done as described in Materials and Methods.  Figure 9C 
shows the absorbance changes plotted as a function of the BNZ concentration. The plot is 
used to determine Ks in the absence (¢) and presence of CYP2E1 (). The Ks values 
were calculated to be 11.4 µM ± 1.10 in the absence of CYP2E1 and to be 339 µM ± 60.2 
in the presence of CYP2E1.  
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KM and kcat Values for the Interaction of CYP2E1 WT with CPR.  To further 
investigate the kinetic basis for the inhibitory characteristics observed for CYP2E1, we 
determined the KM of CYP2E1 for CPR using p-NP as the substrate.  The ability of 
CYP2E1 to inhibit the formation of the CYP2B4 – CPR complex could be attributed to a 
higher affinity (lower KM) of CYP2E1 for CPR compared to CYP2B4.  However, our 
results showed that CYP2E1 and CYP2B4 have essentially the same affinity for CPR.  
CYP2E1 has a KM of 0.02 µM, while CYP2B4 have a KM of 0.15µM, as seen in Table 3.  
Interestingly, when the KM of CYP2E1 for CPR was measured in the presence of 
CYP2B4, a 65% decrease in the KM was observed, as shown in Figure 10 and Table 3.  
The final KM value of 0.08 µM is close to the Ki value of CYP2E1 for the CYP2B4 – 
CPR complex of 0.05 µM.  This suggests that the presence of CYP2B4 enhances the 
formation of the CYP2E1 – CPR complex. 
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Figure 10.  The effect of CYP2B4 on the KM and kcat of CYP2E1 for CPR.  Using a 
fixed concentration of CYP2E1 (0.1 µM) and increasing concentration of CPR, the 
hydroxylation of p-NP was measured in the absence () or presence of 0.1 µM CYP2B4 
(p) as described in Materials and Methods. The error bars are the standard deviations 
from three measurements.	  
Table 3 
 CYP2E1 WT 
 Control Plus CYP2B4 
KM (µM)  0.21 ± 0.030  0.080 ± 0.022 
kcat (min-1)  4.4 ± 0.020  5.8 ± 0.033 
 
Table 3.  The KM and kcat of CYP2E1 WT for CPR in the absence and presence of 
CYP2B4.  Reconstitution mixtures were made of 0.1 µM of CYP2E1 with varying 
concentrations of CPR in the presence and absence of 0.1 µM of CYP2B4.  The 
reconstituted mixtures were added to 50 mM of potassium phosphate buffer (pH 7.4), 0.3 
mM pNP, and 2 mM ascorbic acid after reconstitution.  The reactions were initiated by 
0.0 0.5 1.0 1.5 2.0
0
2
4
6
8
[CPR]µM
n
m
o
l 
4
-N
C
/m
in
/n
m
o
l 
P
4
5
0
43 
adding 0.4 mM NADPH and allowed to proceed for 20 min at 37oC and then they were 
quenched with TCA. Measuring absorbance at 510 nm was used to determine the amount 
of 4-NC formed after the addition of NaOH.  
44 
Discussion:  
 
Despite having known for almost forty years that P450s exist in vast excess over CPR in 
the endoplasmic reticulum, very little is know about the spatial distribution of P450s in 
the membrane (34, 35).  There is even a greater mystery about how the difference in the 
molar ratios of P450 to CPR impacts the pharmacokinetic profile of drugs that mainly 
undergo P450-mediated phase I drug metabolism.  The reductase forms a 1:1 complex 
with P450. Due to the disparity in the molar ratios of P450 and CPR it is highly 
improbable that, at any given time, every P450 will be interacting with a molecule of 
CPR.  From this, it can be inferred that a significant percentage of the total microsomal 
P450 will be spatially incapable of receiving electrons from the CPR, thus these P450s 
are rendered metabolically silent.  Cytochrome b5 (cyt b5) is known to participate in the 
reduction of P450s and therefore may ease the strain imposed by limited CPR 
concentrations.  Cyt b5 has been postulated to only donate the second electron in the P450 
catalytic cycle; however, these results have been highly isoform and substrate-dependent.  
Despite the overall tertiary structure of mammalian P450s being highly conserved, the 
amino acid composition of the regions proposed to interact with CPR is highly variable.  
Thus, there is a possibility that significantly less than stoichiometric amounts of hepatic 
CPR relative to P450, along with variation in the nature of the interactions between 
different P450s and CPR may lead to favorable status for some P450s in the competition 
for CPR. This will have a significant impact on the reduction of the P450 heme and 
bound oxygen, ultimately leading to xenobiotic metabolism.   
 
Often P450s have overlapping specificities.  For a successful study to examine the 
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catalytic consequences of P450 – P450 interactions in a mixed reconstituted system, 
specific substrates for each P450 must be used.  In this study, specific substrates were 
identified for CYP2E1 and CYP2B4.  It is known that CYP2B4 metabolizes BNZ with 
high catalytic activity.  Moreover, BNZ is not metabolized by CYP2E1, even at high 
concentrations of protein and substrate (data not shown).  Additionally, BNZ does not 
induce a spectral change in CYP2E1’s heme, indicating that CYP2E1 does not bind BNZ 
(data not shown), thus BNZ is an excellent substrate to assess CYP2B4 metabolism in a 
reconstituted system containing CYP2E1.  CYP2E1 hydroxylates p-NP to produce 4-NC. 
By measuring the absorbance at 512 nm, 4-NC can be detected spectrophotometrically.  
Furthermore, p-NP is not metabolized by CYP2B4, and CYP2B4 does not bind p-NP.  
Thus BNZ was used as a probe substrate for CYP2B4 activity, while p-NP was used as 
the probe substrate for CYP2E1 activity.  The rate of the first electron transfer, from CPR 
to CYP2E1 and CYP2B4 was also measured in the absence and presence of substrate.  
The results of this experiment showed that BNZ enhances the rate of electron transfer for 
CYP2B4, but BNZ does not enhance the rate for CYP2E1 (data not shown). On the other 
hand, p-NP had no effect on the reduction CYP2B4 or CYP2E1 (data not shown).  From 
these results, we can exclude the possibility that the inhibitory properties of CYP2E1 
towards CYP2B4 are caused by an enhanced transfer process induced by BNZ binding to 
CYP2E1.  
 
By reacting P450s with peroxides such as tert-butyl hydroperoxide (tBHP), P450s are 
capable of generating the ferrous hydro-peroxy intermediate.  The ferrous hydro-peroxy 
intermediate is the precursor to compound I in the catalytic cycle.  The ability of P450s to 
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form the ferrous hydro-peroxy intermediate from reacting with peroxides allows P450s to 
bypass the need of CPR to deliver two electrons and the activated oxygen in the catalytic 
cycle.  This property makes t-BHP a useful experimental tool to examine the catalytic 
integrity of the heme in the absence of CPR.  CYP2B4 activity supported by CPR and 
tBHP were measured to be able to distinguish P450-P450 interactions from P450-CPR 
interactions that maybe responsible for the observed inhibition.  Additionally, the studies 
were done in the presence of excess substrate (1.2 mM BNZ).  The excess substrate 
allows differentiation between the effects of CYP2E1 on CYP2B4’s affinity for CPR 
from CYP2E1’s effect on CYP2B4’s affinity for its substrate, BNZ.  The results of the 
experiment showed that CYP2B4 was resistant to inhibition by CYP2E1 in the presence 
of tBHP.  While CYP2B4 lost up to 80% of its BNZ activity in the presence of CPR, 
these results suggest that CPR is implicated in the inhibitory phenomenon observed in 
Figure 3A.  We investigated whether the CYP2E1 variant (Y422D) could alter the extent 
of inhibition of CYP2B4 to further analyze the contribution of CYP2E1 – CPR 
interactions to the inhibition of CYP2B4. The CYP2E1 variant (Y422D) has a mutation 
in the proximal site that reduces its apparent binding to CPR by approximately 50%, as 
shown in Figure 4.  The results showed that the extent of CYP2B4 inhibition by the 
CYP2E1 variant is significantly less than WT CYP2E1. These results also support the 
suggestion that CYP2E1 – CPR interactions have a role in the loss of CYP2B4 activity 
supported by CPR.   
 
Furthermore, the data acquired for the KM of CYP2B4 for CPR supports the idea that 
CYP2E1 interferes with CYP2B4 – CPR complex formation.  The CYP2B4 KM value for 
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CPR demonstrated that low concentrations of CYP2E1 elevated the KM for CPR by up 
to13-fold with a negligible effect on kcat relative to samples that did not include CYP2E1.  
At higher concentrations of CYP2E1, there is decease in the KM of CYP2B4 for CPR but 
there is a concomitant reduction in the kcat by 13-fold.  Inverse plots of velocity as a 
function of CPR concentration exposes that CYP2E1 behaves as both a competitive and 
noncompetitive inhibitor of the CYP2B4 – CPR interaction.  We plotted KM obs as a 
function of CYP2E1 concentrations to approximate a kinetic constant for the observed 
competitive inhibition portion of CYP2E1 on CYP2B4.  Then a linear regression analysis 
of this plot produced a straight line, which intersected with the x-axis at -0.05µM.  This 
linear regression plot demonstrates that inhibition of CYP2B4 by CYP2E1 is very potent.  
Furthermore, a global non-linear analysis done by GraphPad prism of the same data 
revealed a similar Ki.  
 
These results are intriguing to contemplate, especially in relation to the P450’s individual 
KM values for CPR.  For two P450s that are competing for the same functional binding 
site of CPR, the specificity should be determined by the individual KM values of the 
P450s for CPR.  That is, the specificity will distinguish between binding of the two 
competing P450s for CPR.  However, the KM values measured for CYP2B4 and CYP2E1 
for CPR are virtually identical.  The KM value of CYP2B4 for CPR was 0.16 µM while 
the K M of CYP2E1 for CPR was 0.20 µM.  Thus, it would be expected that both P450s 
could compete with each other equally for CPR.  However, the data indicates that 
CYP2E1 is significantly more effective at competing with, whereas 2B4 did not compete 
with 2E1 for CPR as shown in Figure 3.  This inconsistency in the competition between 
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CYP2B4 and CYP2E1 suggested that the competition between CYP2B4 and CYP2E1 for 
CPR did not proceed through a competitive binding of CPR.  Backes and co-workers 
have suggested that the presence of one P450 may enhance the affinity of an other P450 
for CPR (41).  Determining the KM and kcat of CYP2E1 for CPR in the absence and 
presence of CYP2B4 showed that the kcat increased by 1.4-fold to 5.8 min-1, while the KM 
decreased by 65% to 0.08µM.  Remarkably, this value of the enhanced KM is comparable 
to the Ki of CYP2E1 for the CYP2B4 – CPR complex.  Hence, this data supports the idea 
that a decrease in the KM of CYP2E1 for CPR in the presence of CPY2B4 may impact 
the inhibitory properties of CYP2E1. 
 
One possible mechanism to explain the observed interactions would involve the 
conformational trapping of CPR by CYP2B4 and/or CYP2E1.  The model for these 
interaction is illustrated in Figure 11.  This model is based on a couple findings. The first 
finding is that the direct CYP2B4 – CYP2E1 interaction alone does not lead to inhibition 
of CYP2B4 activity in the presence of saturating concentrations of BNZ, as shown in 
Figure 3A.  Secondly, this model is supported by the observation that CYP2B4 and 
CYP2E1 interact directly reduce the affinity of CYP2B4 for BNZ as shown in Figure 9.  
Additionally, the model is based on the observation that CYP2E1 has a higher KM for 
CPR in the presence of CYP2B4 (Figure 10).  It has been well established that 
macromolecular structures such as enzymes and RNA may experience conformational 
changes in solutions (75, 80).  These conformational changes are necessary for their 
catalytic activity (81).  The electron density of the hinge region connecting the FMN 
domain to the FAD domain in CPR is often disordered in the CPR crystal structures (82).  
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Recently completed mutagenesis studies have demonstrated that the hinge region plays a 
significant role in moving the two-flavin domains of CPR apart from each other.  A 
disulphide bond, which is specifically engineered to hold the domains in place, limits this 
movement.  With the disulphide bond in place, it was found that CPR exhibited a loss in 
activity (83).  Since CPR posseses this highly flexible hinge region, a potential 
explanation for the enhancement of the KM of CYP2E1 for CPR may be from a 
conformational trapping of CPR.  CPR may be conformationally trapped by the binding 
of 2B4 at a non-functional site of CPR, trapping CPR in a specific conformation that 
makes it more favorable for CYP2E1 to bind at the proposed functional site, FMN.  On 
the other hand, it is just as probable that CYP2E1 binds to CPR functional site and then 
traps CPR in a specific conformation.  In this conformation, it may be more favorable for 
CYP2B4 to bind at the non-funcational site of CPR.  
 
 
Figure 11. A tentative model for the CYP2B4-CYP2E1 synergistic interaction. Upon 
binding to a non-functional site on CPR, CYP2B4 traps CPR in a particular conformation 
that makes it more favorable for CYP2E1 to bind to the FMN domain or CYP2E1 binds 
at the functional site on CPR and traps CPR it in a particular conformation that makes it 
more favorable for CYP2B4 to bind at CPR’s non-functional site. Both scenarios may 
give rise to an enhanced KM of CYP2E1 for CPR. 
 
In past studies that have examined the interactions between different P450s, the 
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inhibitory nature of CYP2E1 towards CYP2B4-mediated metabolism of BNZ and the 
enhancement of CYP2E1’s KM for CPR while using p-NP as the probe substrate has gone 
undetected.  Studies by Kelly et. al. (53) have established that interactions between 
CYP1A2 and CYP2E1 result in a significantly enhanced rate of 7-ethoxyresorufin (7-ER) 
and 7-pentoxyresorufin (7-PR) metabolism.  Nevertheless, when the interactions between 
CYP2E1 and CYP2B4 were investigated using 7-ER, 7-PR, and aniline as substrates, no 
functional interactions between CYP2E1 and CYP2B4 were observed.  These results 
suggest that CYP2E1 and CYP2B4 do not form a P450 – P450 complex.  Thus, the 
differences between the results of Kelly et al and our own are probably due to different 
isoforms of P450s used in the study, along with modification of the substrates used.  As it 
has been previously shown, the interactions between P450s are dependent on the 
substrates under investigation (34). 
 
Vatsis et. al. (84) demonstrated that by replacing the cysteine 436 with a serine in 
CYP2B4, that the mutant protein has the same KM for reductase but is catalytically 
inactive.  The CYP2B4 C436S mutant is unable to cleave the O-O bond in the catalytic 
cycle (84).  By use of this mutant, we attempted to examine the reduction step of 
CYP2B4 C463S in the presence of CYP2E1 to better understand the interactions between 
CYP2B4 and CYP2E1.  This study would be the most direct way of studying interactions 
between CYP2E1, CYP2B4, and CPR.  However, since both P450s absorb at the same 
wavelength (450 nm) when following reductions in the presence of CO, it was not 
possible to distinguish between the two isoforms during the reduction reaction.  However, 
the CYP2B4 C463S absorbs at a different wavelength than CYP2E1, thus allowing the 
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isoforms to be distinguished.  Unfortunately, in spite of our best attempts to express and 
purify the CYP2B4 C465S holoprotein, our attempts resulted in the production of 
significant amount apo-protein.  Due to structural differences between the apo-protein 
and holo-protein, results from studies examining the competition for CPR would be 
skewed.  Furthermore, the study involves titration of the mutant protein and due to the 
presence of the apo-protein, it would be difficult to quantify the amount of apo-protein, 
thus making the concentration of active P450 added unknown for the competition 
experiment.  
 
To further understand the interactions occurring between CYP2B4, CYP2E1 and CPR 
there are a couple areas for future to studies.  Sligar’s lab has been examining P450s 
following incorporation into Nanodiscs, which are soluble nanoscale lipid bilayers (85).  
These Nanodiscs provide a model membrane system to study membrane proteins.  They 
under go a simple self-assembly of a small lipid bilayer that is solubilized by a membrane 
scaffold protein along with the membrane protein of study.  In Sligar’s lab they have been 
able to successfully incorporate a single P450 and CPR into a Nanodisc.  The Nanodisc 
technology would provide an alternative to studies in liposomes.  By examining the 
interactions of CYP2B4, CYP2E1, and CPR in Nanodiscs the results of the studies will 
allow differentiation of the effects of oligomers on P450-P450 interactions.  The results 
of these experiments will give greater insight to isoform interaction in vivo.  Work on this 
project has begun; I started working on a procedure for the incorporation of CYP2E1 and 
CPR into Nanodiscs.  The ultimate goal of this study would be to successfully 
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incorporate CYP2B4, CYP2E1, and CPR into a single Nanodisc to allow for further 
study.  
 
Woodward et. al. have developed a method for the incorporation of heme analogs without 
exposing the protein to harsh denaturing conditions (86).  This methodology allowed for 
the replacement of the heme iron with another transition metal in Nitric Oxide Synthase 
(NOS). NOS has been found to be very similar to P450.  They both are heme-thiolate 
proteins, which have the same prosthetic group to perform similar oxidative reactions 
(87).  In both P450 and NOS the electrons are supplied by a flavorprotein reductase, 
where the reductase is an integral part of the NOS (87).  The structural and functional 
similarities between P450 and NOS make the methodology of Woodward et. al. 
promising for achieving iron replacement in P450s.  The replacement of the heme iron 
with a transition metal would result in the P450 only weakly binding CO, and would 
result in silencing of one P450 at a time.  With the ability to selectively silence an 
individual P450 isoform it would be possible to examine in greater detail interactions 
between P450 isoforms. For our studies the ability to selective silence a P450 would 
allow for greater opportunities to examine and understand the interactions between 
CYP2E1 and CYP2B4.  
 
In the big pharmaceutical company setting a significant amount of effort is made to 
understand and predict in vivo pharmacokinetic profiles of drugs and compounds from in 
vitro data (88).  Protein-protein interactions in the P450 system, such as the ones 
described here, may confound in vitro – in vivo drug metabolism extrapolations.  Thus, it 
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is critical that in-depth kinetic studies are conducted to determine the kinetic basis and 
associated kinetic constants that govern these interactions. Obtaining information from 
studies such as these is invaluable, as this information will play an important role in 
improving our ability to predict, for example, drug clearance and drug-drug interactions 
from in vitro data.   
 
The conclusions presented in this paper illustrate that human CYP2E1 is an inhibitor of 
CYP2B4 activity.  This inhibition by CYP2E1 is mediated indirectly through competition 
for CPR, while also being through direct CYP2E1 – CYP2B4 interactions.  It was 
necessary to distinguish between CYP2E1 inhibition of CYP2B4 activity that is mediated 
directly by the CYP2E1-CYP2B4 interactions from competition between these two P450s 
for CPR.  In order to differentiate between these types of inhibition, we evaluated 
whether increasing concentrations of CYP2E1 could inhibit CYP2B4’s activity supported 
by tBHP in the absence of CPR and with a saturating concentration of BNZ.  The results 
of this experiment showed that the loss in CYP2B4 activity was minimal in comparison 
to CYP2B4’s loss in activity in the presence of CPR.  Thus, we were able to conclude 
that inhibition of CYP2B4 by CYP2E1 under saturating concentrations of substrate is 
probably mediated by competition for CPR. The results from determining CYP2B4’s KM 
for CPR under varying concentrations of CYP2E1 established that CPR was implicated in 
the inhibitory action of CYP2E1 and the measurements of CYP2E1’s KM for CPR were 
significantly enhanced by the presence of CYP2B4.  Additionally, it was observed that 
CYP2E1 can perturb CYP2B4’s affinity for BNZ as established by measurement of 
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BNZ’s substrate dissociation constant for CYP2B4 in the absence and presence of 
CYP2E1. 
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